Optimizing dose for Lu-177 DOTA-rituximab lymphoma therapy

July 16, 2013

Radioimmunotherapy with Lu-177 DOTA-rituximab represents a novel and well-matched treatment for B-cell Lymphoma, but no consensus on standardized dosimetry was available, until now, according to research published in the July issue of Journal of Nuclear Medicine.

Flavio Forrer, MD, from the Institute of Nuclear Medicine at University Hospital Basel in Basel, Switzerland, and colleagues evaluated the maximum tolerated dose of chimeric anti-CD20 antibody rituximab conjugated with luteum-177 treating patients with recurrent or refractory CD20-positive mantle cell, follicular or marginal zone and other indolent lymphomas in this prospective, single-center and open-label phase I/II dose escalation study.